According to a recent LinkedIn post from Subsense, the company is developing a pre‑clinical brain‑computer interface that aims to enable bidirectional neural conversation using nanoscale materials. The post highlights an intranasal delivery approach that would transport biocompatible nanoparticles into the brain, where external magnetism is intended to guide them into position.
The post further indicates that magnetoelectric particles are designed to translate signals from a wearable device into gentle electrical prompts for nearby neurons, while plasmonic particles are meant to read neural activity by altering near‑infrared light scattering. Subsense emphasizes that the work remains pre‑clinical and that safety considerations are guiding each stage of development.
For investors, the content suggests Subsense is pursuing a differentiated, minimally invasive brain‑computer interface architecture that could expand the addressable market for neurotechnology if successfully validated. However, the early‑stage and safety‑focused status implies a long development timeline, significant technical risk, and likely substantial funding needs before any commercial revenue, positioning the company more as a speculative innovation play within the neurotech sector.